deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02110563

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Conditions Multiple Myeloma NHL Non-Hodgkins Lymphoma PNET Pancreatic Neuroendocrine Tumors Solid Tumors
Interventions DCR-MYC
Updated 10 times since 2017 Last updated: Jul 10, 2024 Started: Apr 30, 2014 Primary completion: Oct 5, 2016 Completion: Nov 3, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor Decision

Other terminated trials from Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

See all terminations from Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

This PHASE1 trial investigates Multiple Myeloma and NHL and is currently terminated or withdrawn. Dicerna Pharmaceuticals, Inc., a Novo Nordisk company leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotActive Not Recruiting~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshotTerminated~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~May 2023 · 28 months · monthly snapshotTerminated~May 2023 – ~Jul 2024 · 14 months · monthly snapshotTerminated~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshotTerminated~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Aug 2024 [monthly]

    Terminated PHASE1

  4. May 2023 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Jan 2021 — May 2023 [monthly]

    Terminated PHASE1

▶ Show 5 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  2. Dec 2017 — Jun 2018 [monthly]

    Terminated PHASE1

  3. Aug 2017 — Dec 2017 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  4. Feb 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations